Chimeric Antigen Receptor Macrophage Therapy

Satricabtagene autoleucel improved PFS compared with physician’s choice of therapy for patients with Claudin18.2 expression-positive advanced gastric or gastroesophageal junction cancers, according to the agent’s manufacturer.

Patients who received chimeric antigen receptor T-cell therapy did not exhibit increased risk for second primary malignancies compared with those who received other standard treatments, according to a systematic review and meta-analysis.

Infections are the primary cause of nonrelapse mortality among individuals who undergo chimeric antigen receptor T-cell therapy, according to study results.

A novel immunotherapy approach for solid, epithelial cancers reduced tumor burden among multiple patients with metastatic colon cancer, according to phase 2 study results.

Obecabtagene autoleucel conferred durable benefit to certain patients with relapsed or refractory B-cell acute lymphoblastic leukemia, according to results of the phase 1B/phase 2 FLEIX study presented at ASCO Annual Meeting.

FDA has scaled back its Risk Evaluation and Mitigation Strategy reporting requirements for providers of chimeric antigen receptor T-cell therapies.

Jae Park, MD, compared the moment to a baby being born.

A simultaneous, multidrug, multi-targeted treatment regimen produced remissions in patients with certain types of relapsed or refractory diffuse large B-cell lymphoma in a phase 1b/phase 2 study.

A phase 1 trial showed chimeric antigen receptor T-cell therapy may hold promise for the treatment of glioblastoma.

Individuals with relapsed or refractory lymphoma who received chimeric antigen receptor T-cell therapy experienced a wide range of adverse events compared with those who received other treatments, study results showed.